AMDL, Inc. Announces Strategic R...((s) or selling the division as a stand-a...)

-- Continue accelerating the manufacturing, sales & marketing of AMDL's

diverse China-based pharmaceutical product portfolio through the

Integrated Pharmaceuticals division; and,

-- Leverage AMDL's current assets and resources to drive future growth.

"Segmenting AMDL's operations into these three distinct divisions provides us with greater market focus, increased flexibility across our diverse product portfolio, and a solid platform to successfully execute AMDL's key business goals," commented Mr. Gary Dreher, President and CEO of AMDL. "We've achieved significant growth in sales and gross profits over the past 18 months and believe this refinement will strengthen AMDL's long-term growth position as a leading developer, manufacturer and supplier of high-quality diagnostic and pharmaceutical products."

For additional information on AMDL and its diversified product portfolio visit the Company's website at http://www.amdl.com or contact AMDL Investor Relations at 206.310.5323.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs approximately 320 people in the U.S. and China. The Company has an additional 4 pharmaceutical and diagnostic products under review by various regulatory authorities.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statem
'/>"/>